Premium Subscribers: Complete your KYC to Avoid
Service Suspension. Login Here.

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BLISS GVS PHARMA Gains 4%; BSE HEALTHCARE Index Up 0.2%
Wed, 7 Jan 9:38

BLISS GVS PHARMA Gains 4%; BSE HEALTHCARE Index Up 0.2%Image source: hudiemm/www.istockphoto.com

BLISS GVS PHARMA share price has zoomed 4% and is presently trading at Rs 189.4.

Meanwhile, the BSE HEALTHCARE index is at 44,689.4 (up 0.2%).

Among the top gainers in the BSE HEALTHCARE index today are Natco Pharma (up 2.0%) and Biocon (up 1.7%).

Cipla (down 2.4%) and METROPOLIS HEALTHCARE (down 2.3%) are among the top losers today.

Over the last one year, BLISS GVS PHARMA has moved up from Rs 166.9 to Rs 189.4, registering a gain of Rs 22.5 (up 13.5%).

On the other hand, the BSE HEALTHCARE index has moved down from 44,953.7 to 44,689.4, registering a loss of 0.6% during the last 12 months.

The top losers among the BSE HEALTHCARE index stocks during this same period were COHANCE LIFESCIENCES (down 53.6%), POLY MEDICURE (down 37.8%) and SUN PHARMA ADV. RES. (down 29.0%).

Peak India: The Rally of the Past 5 Years was Just a Preview

What About the Benchmark Indices?

The BSE Sensex is at 84,883.1 (down 0.2%).

The top losers among the BSE Sensex today are Tata Motors (down 2.0%) and Bharti Airtel (down 1.2%). The most traded stocks in the BSE Sensex are HDFC Bank and ITC.

In the meantime, NSE Nifty is at 26,133.3 (down 0.2%). Cipla and Tata Motors are among the top losers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 77,965.0 to 84,883.1, registering a gain of 6,918.1 points (up 8.9%).

BLISS GVS PHARMA Financial Update...

BLISS GVS PHARMA net profit grew 11.3% YoY to Rs 286 million for the quarter ended September 2025, compared to a profit of Rs 257 million a year ago. Net sales rose 12.3% to Rs 2,444 million during the period as against Rs 2,177 million in July-September 2024.

For the year ended March 2025, BLISS GVS PHARMA reported 10.6% increase in net profit to Rs 903 million compared to net profit of Rs 816 million during FY24. Revenue of the company grew 5.1% to Rs 8,097 million during FY25.

The current Price to earnings ratio of BLISS GVS PHARMA, based on rolling 12 month earnings, stands at 17.4.


Equitymaster requests your view! Post a comment on "BLISS GVS PHARMA Gains 4%; BSE HEALTHCARE Index Up 0.2%". Click here!